Prospective Study of Pravastatin in the Elderly at Risk (PROSPER)

Principal Investigators

Contact: Behnam Sabayan
Clinical Neuroscience-Cerebrovascular Changes in Ageing and Dementia
Northwestern University


Countries Scotland, Ireland, Netherlands
Principal Investigator PROSPER study group
Contact person (email) behnam.sabayan@northwestern.edul
Key publication/reference Shepherd et al. Lancet (2002)
Years in which study conducted 1997-2001
Size 5804 (649 with history of stroke/TIA)
Population: Hospital/community  
Selection: consecutive/random Selected based on a history of, or risk factors for, vascular disease
Admit with previous stroke or TIA Yes: n=649 (321 placebo, 328 Pravastatin)
Admit with TIA? Yes
Age range 70–82 years
Number of centres 3
Control group: number, population, selection Yes: Randomised controlled trial
Initial: Time and data collected/tests administered Baseline, 9m, 18m, 30m, end of study
Subsequent (follow-ups) Up to 3.2 y (mean)
Stroke-related data ---
Functional tests/data ADLs and IADLs
Other medical tests/data CV risk factors, blood analysis, genotyping, medication and  metabolic data
Neuropsychological tests MMSE and test battery
MRI scans, when and how many Baseline and at the end of trial (n=553)
PET scans No
Psychiatric exams/diagnoses GDS (subset)
Intervention trialled? Pravastatin

CT=computed tomography scan, MedHx=medical history, VRF=vascular risk factors (hypertension, diabetes, atrial fibrillation, obesity, smoking etc.), NΨ=neuropsychological, TIA=transient ischemic attack, m=month, y=year